Dr. Joseph D. Rosenblatt, MD

Dr. Rosenblatt practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Rosenblatt's NPI, 1497770499, was assigned on July 12, 2006. Dr. Rosenblatt graduated from David Geffen School of Medicine at UCLA in 1980. Dr. Rosenblatt holds Florida license ME88673.

Dr. Rosenblatt's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Rosenblatt's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Rosenblatt is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rosenblatt practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Rosenblatt's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Rosenblatt is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Rosenblatt's licenses on file in 3 states: Florida, California and New York.

Dmand AI lists chronic anemia, chronic leukemia, lymphoma, multiple myeloma, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Rosenblatt treats.

CMS data shows 237 Medicare services from Dr. Rosenblatt across 3 procedure codes in 2024, for 109 Medicare patients. Medicare paid $16,199 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 109 Medicare patients who saw Dr. Rosenblatt in 2024. The largest group is 75 to 84, with 58 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 15% are also on Medicaid. Their average risk score is 2.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rosenblatt's median patient age at 75, with 38% women.

In 2024, Dr. Rosenblatt wrote 310 Medicare Part D claims for 32 patients. CMS names the drug for 217 of them, across 8 drugs with 11 or more claims each, at $1,671,726 in total drug cost. In 2023, CMS named 245 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Rosenblatt for performance year 2024, reported as part of a group. Dr. Rosenblatt accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rosenblatt as offering telehealth.

Dmand AI links 135 papers to Dr. Rosenblatt, published from 2005 to 2025. 2016 was the busiest year, with 5. The most frequent topics are T-Lymphocytes, Base Sequence and Human T-lymphotropic virus 1. Dr. Rosenblatt has published most often in Blood. Dr. Rosenblatt's most frequent co-authors are Izidore Lossos, MD, Isan Chen, MD and Juan Pablo Alderuccio, MD.

Dmand AI links Dr. Rosenblatt to 3 clinical trials. Conditions studied include Lymphoma, B-Cell, Marginal Zone, Melanoma and Lymphoma, Follicular. University of Rochester sponsors the most, 2.

CMS Open Payments shows 105 general payments to Dr. Rosenblatt from 20 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 73% of the total. Merck Sharp & Dohme Corporation paid the most, $7,606.

Dmand AI lists 5 awards for Dr. Rosenblatt, most recently America's Top Doctors in 2014.

Dr. Rosenblatt graduated from David Geffen School of Medicine at UCLA in 1980.

Dr. Rosenblatt is in network with 11 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.